Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model

AACR 2023 -- Establishing long-term CAR T persistence and efficacy remains a barrier to broader application of CAR T therapies in the clinic, thus development of robust platforms that can provide longitudinal assessments of CAR T persistence and functionality is paramount. Using the NALM6-Luc ALL model, Labcorp Drug Development has developed a flow cytometry platform that provides quantitative analysis of CAR T cells over time as well as surface markers that are documented to correlate with sustained T cell persistence, activation and exhaustion in vivo.

Filed In

Preclinical & Nonclinical